home / stock / atha / atha short
Short Information | Athira Pharma Inc. (NASDAQ:ATHA)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 282,199 |
Total Actual Volume | 2,450,659 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 14,110 |
Average Short Percentage | 12.63% |
Is there a ATHA Short Squeeze or Breakout about to happen?
See the ATHA Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $2.52 | $2.57 | $2.65 | $2.48 | 74,169 | 9,005 | 12.14% |
07-02-2024 | $2.51 | $2.52 | $2.5399 | $2.46 | 62,591 | 10,928 | 17.46% |
07-01-2024 | $2.61 | $2.51 | $2.64 | $2.49 | 45,594 | 6,166 | 13.52% |
06-28-2024 | $2.66 | $2.65 | $2.69 | $2.56 | 120,897 | 16,368 | 13.54% |
06-27-2024 | $2.43 | $2.64 | $2.65 | $2.43 | 144,711 | 11,304 | 7.81% |
06-26-2024 | $2.31 | $2.41 | $2.42 | $2.2515 | 89,270 | 4,805 | 5.38% |
06-25-2024 | $2.36 | $2.19 | $2.37 | $2.13 | 154,605 | 23,068 | 14.92% |
06-24-2024 | $2.37 | $2.37 | $2.431 | $2.32 | 61,648 | 18,811 | 30.51% |
06-21-2024 | $2.27 | $2.34 | $2.36 | $2.18 | 121,272 | 15,563 | 12.83% |
06-20-2024 | $2.58 | $2.29 | $2.58 | $2.28 | 91,871 | 18,066 | 19.66% |
06-18-2024 | $2.59 | $2.6 | $2.65 | $2.52 | 147,544 | 11,060 | 7.5% |
06-17-2024 | $2.53 | $2.6 | $2.61 | $2.48 | 95,981 | 11,610 | 12.1% |
06-14-2024 | $2.52 | $2.54 | $2.56 | $2.47 | 145,877 | 17,545 | 12.03% |
06-13-2024 | $2.59 | $2.55 | $2.61 | $2.53 | 94,138 | 10,860 | 11.54% |
06-12-2024 | $2.61 | $2.6 | $2.64 | $2.53 | 135,513 | 25,421 | 18.76% |
06-11-2024 | $2.53 | $2.55 | $2.61 | $2.475 | 70,213 | 6,144 | 8.75% |
06-10-2024 | $2.52 | $2.55 | $2.59 | $2.47 | 171,136 | 15,047 | 8.79% |
06-07-2024 | $2.51 | $2.55 | $2.5846 | $2.44 | 198,177 | 17,751 | 8.96% |
06-06-2024 | $2.57 | $2.54 | $2.622 | $2.4611 | 258,495 | 14,810 | 5.73% |
06-05-2024 | $2.46 | $2.57 | $2.58 | $2.46 | 166,957 | 17,867 | 10.7% |
News, Short Squeeze, Breakout and More Instantly...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western Distri...